Sinovac Biotech Ltd.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sinovac Biotech Ltd. (SVA) is a China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines protecting against human infectious diseases. The company offers a portfolio of approved vaccines including COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac; Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive; Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive; Hepatitis A & Hepatitis B Combined Vaccine - Bilive; Influenza Vaccine (Split Virion), Inactivated, Quadrivalent and Anflu; Pandemic Influenza Vaccine (Inactivated, Adjuvanted) - Panflu; H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1; 23-valent Pneumococcal Polysaccharide Vaccine; Varicella Vaccine, Live - PROVARIX; Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains; and Mumps Vaccine (Live). Sinovac Biotech Ltd. operates primarily in China with international market presence, supplying vaccines to over 60 countries and regions, and maintains subsidiaries in locations such as Dalian and Tangshan. Founded in 1999 and headquartered at No. 39 Shangdi Xi Road, Haidian District, Beijing, China, the company targets governmental immunization programs and public health initiatives. Recent developments include WHO prequalification of its Sabin-strain inactivated polio vaccine and varicella vaccine in 2022; authorization of Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Five-Dose) by China NMPA in April 2024; significant growth in international sales of Healive in the first half of 2024; and its Türkiye joint venture securing long-term public tenders for hepatitis A and varicella vaccines in 2024.
SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
SINOVAC Reports Unaudited First Half of 2025 Financial Results
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
SINOVAC Announces Appointment of Independent Auditor
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
Newly Elected Directors of Sinovac Hold the First Board Meeting
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2